Literature DB >> 2910510

Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas.

S Tura1, P Mazza, F Gherlinzoni, P L Zinzani, G Poletti, G Visani, R M Lemoli, M Cavo, P Galieni, C Tassi.   

Abstract

In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed after other chemotherapy. PTT was scheduled by escalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) showed a good response (CR + PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2910510     DOI： 10.1007/BF00273532

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  8 in total

1.  Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in advanced non-Hodgkin's lymphomas.

Authors:  C S Portlock; S A Rosenberg
Journal:  Cancer       Date:  1976-03       Impact factor: 6.860

2.  [Therapeutic effectiveness of PTT-119 evaluated in vivo in experimental models].

Authors:  R Bianchi; B Nardelli; M Allegrucci; M C Fioretti
Journal:  G Ital Chemioter       Date:  1985 Jan-Apr

3.  Synthesis, acute toxicity and chemotherapeutic anti-cancer activities of a new tripeptidic mustard.

Authors:  A De Barbieri; L Dall'Asta; A Comini; V Springolo; P Mosconi; G Coppi
Journal:  Farmaco Sci       Date:  1983-04

4.  PTT.119, p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met ethoxy HCl, a new chemotherapeutic agent active against drug-resistant tumor cell lines.

Authors:  M J Yagi; S E Chin; K J Scanlon; J F Holland; J G Bekesi
Journal:  Biochem Pharmacol       Date:  1985-07-01       Impact factor: 5.858

5.  Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.

Authors:  E M McKelvey; J A Gottlieb; H E Wilson; A Haut; R W Talley; R Stephens; M Lane; J F Gamble; S E Jones; P N Grozea; J Gutterman; C Coltman; T E Moon
Journal:  Cancer       Date:  1976-10       Impact factor: 6.860

6.  Increased cancericidal activity of PTT.119; a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. II. In vivo bioassay.

Authors:  M J Yagi; M Zanjani; J F Holland; J G Bekesi
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.

Authors:  R I Fisher; V T DeVita; S M Hubbard; D L Longo; R Wesley; B A Chabner; R C Young
Journal:  Ann Intern Med       Date:  1983-03       Impact factor: 25.391

8.  Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.

Authors:  P S Schein; V T DeVita; S Hubbard; B A Chabner; G P Canellos; C Berard; R C Young
Journal:  Ann Intern Med       Date:  1976-10       Impact factor: 25.391
  8 in total
  2 in total

1.  Phase II cooperative study with a new alkylating drug, PTT-119, in the treatment of non-Hodgkin's lymphomas.

Authors:  F Gherlinzoni; P Mazza; P L Zinzani; S Tura; F Lanza; G Castoldi; G Bellesi; P L Rossi Ferrini; L Mangoni; V Rizzoli
Journal:  Blut       Date:  1990-03

2.  Evidence for increased intracellular transport of m-sarcolysine (alkylating moiety) when combined with two amino acid analogs (PTT-119).

Authors:  F Verlicchi; S Boschi; G Visani; A Guidi; P Tosi; M Cavo; S Tura
Journal:  Blut       Date:  1990-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.